Breaking News Instant updates and real-time market news.

NVS

Novartis

$80.89

2.17 (2.76%)

08:57
07/19/18
07/19
08:57
07/19/18
08:57

Novartis upgraded to Equal Weight from Underweight at Barclays

NVS Novartis
$80.89

2.17 (2.76%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/12/18
PIPR
07/12/18
NO CHANGE
Target $95
PIPR
Neutral
PTAB decision on Gilenya positive for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.
07/16/18
MSCO
07/16/18
INITIATION
Target $37
MSCO
Overweight
AvroBio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated AvroBio (AVRO) with an Overweight rating and $37 price target, noting that its a unique gene therapy company that has human clinical data for one of its programs at the time of its initial public offering. He points to Novartis' (NVS) recent acquisition of AveXis for $8.7B, or an 88% premium, as an illustration of the substantial interest in and valuation premium put into many names in the gene therapy space.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.

TODAY'S FREE FLY STORIES

KSS

Kohl's

$65.28

0.83 (1.29%)

10:40
11/21/18
11/21
10:40
11/21/18
10:40
Options
Bullish call spread in Kohls after recent weakness in shares »

Bullish call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:40
11/21/18
11/21
10:40
11/21/18
10:40
General news
The U.S. 1.4% October existing home sales rise »

The U.S. 1.4% October…

10:40
11/21/18
11/21
10:40
11/21/18
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

DE

Deere

$145.63

7.14 (5.16%)

10:37
11/21/18
11/21
10:37
11/21/18
10:37
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere raises 2022…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

DE

Deere

$144.30

5.81 (4.20%)

10:32
11/21/18
11/21
10:32
11/21/18
10:32
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere sees grain demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

10:31
11/21/18
11/21
10:31
11/21/18
10:31
General news
Crude inventories for week of November 16 »

Crude oil inventories…

JNJ

Johnson & Johnson

$143.12

-3.32 (-2.27%)

10:30
11/21/18
11/21
10:30
11/21/18
10:30
Options
J&J puts active as shares see relative weakness »

J&J puts active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

10:30
11/21/18
11/21
10:30
11/21/18
10:30
General news
FX Action: The dollar »

FX Action: The dollar…

DE

Deere

$143.26

4.77 (3.44%)

10:29
11/21/18
11/21
10:29
11/21/18
10:29
Hot Stocks
Deere says U.S. farmers, dealers 'cautiously optimistic' »

Says record yields,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

AVGO

Broadcom

$229.32

1.63 (0.72%)

, VLKAY

Volkswagen

$0.00

(0.00%)

10:28
11/21/18
11/21
10:28
11/21/18
10:28
Periodicals
Breaking Periodicals news story on Broadcom, Volkswagen »

Broadcom said to settle…

AVGO

Broadcom

$229.32

1.63 (0.72%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMZN

Amazon.com

$1,520.59

24.99 (1.67%)

10:27
11/21/18
11/21
10:27
11/21/18
10:27
Periodicals
Amazon contacting some users about error that exposed emails, The Verge says »

Amazon has been emailing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

10:25
11/21/18
11/21
10:25
11/21/18
10:25
General news
U.S. leading index rose 0.1% to 112.1 in October, another record high »

U.S. leading index rose…

TLC

Taiwan Liposome

$0.00

(0.00%)

10:21
11/21/18
11/21
10:21
11/21/18
10:21
Syndicate
Taiwan Liposome opens at $6.06, IPO priced at $5.80 per share »

Taiwan Liposome (TLC)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NVDA

Nvidia

$150.33

1.19 (0.80%)

10:20
11/21/18
11/21
10:20
11/21/18
10:20
Technical Analysis
Technical Take: Nvidia goes negative on the day »

At time of writing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
U.S. October existing home sales bounced 1.4% to 5.220 M »

U.S. October existing…

JD

JD.com

$20.24

0.75 (3.85%)

10:20
11/21/18
11/21
10:20
11/21/18
10:20
Options
Third day of call buying in JD »

Third day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
Treasury Action: yields steadied above lows »

Treasury Action: yields…

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
The Michigan sentiment drop »

The Michigan sentiment…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/21/18
11/21
10:17
11/21/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/21/18
11/21
10:16
11/21/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
11/21/18
11/21
10:15
11/21/18
10:15
General news
Breaking General news story  »

Week of 11/16 EIA…

WDC

Western Digital

$46.68

0.99 (2.17%)

10:10
11/21/18
11/21
10:10
11/21/18
10:10
Options
Western Digital weekly calls active as shares gain 3% »

Western Digital weekly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

10:10
11/21/18
11/21
10:10
11/21/18
10:10
General news
U.S. consumer sentiment fell 1.1 points to 97.5 in the final November print »

U.S. consumer sentiment…

BGNE

BeiGene

$126.50

0.63 (0.50%)

, GMDA

Gamida Cell

$9.50

(0.00%)

10:09
11/21/18
11/21
10:09
11/21/18
10:09
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

BGNE

BeiGene

$126.50

0.63 (0.50%)

GMDA

Gamida Cell

$9.50

(0.00%)

MRKR

Marker Therapeutics

$6.37

0.11 (1.76%)

ARCE

Arco Platform

$22.65

(0.00%)

NVT

nVent Electric

$24.43

0.25 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 01

    Dec

  • 03

    Dec

  • 07

    Dec

LOW

Lowe's

$86.80

0.65 (0.75%)

, GS

Goldman Sachs

$193.69

2.35 (1.23%)

10:09
11/21/18
11/21
10:09
11/21/18
10:09
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…

LOW

Lowe's

$86.80

0.65 (0.75%)

GS

Goldman Sachs

$193.69

2.35 (1.23%)

CS

Credit Suisse

$11.93

0.21 (1.79%)

SWGAY

Swatch Group

$0.00

(0.00%)

LNT

Alliant Energy

$44.64

-0.62 (-1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.